array(40) {
  [0]=>
  string(4) "8405"
  ["article_id"]=>
  string(4) "8405"
  [1]=>
  string(59) "German govt and Euro hemp trade group clash over CBD status"
  ["article_title"]=>
  string(59) "German govt and Euro hemp trade group clash over CBD status"
  [2]=>
  string(150) "The German Food and Agriculture Ministry (BMEL) has refuted an EU hemp group missive that the Ministry had changed its position regarding the novel fo"
  ["short_description"]=>
  string(150) "The German Food and Agriculture Ministry (BMEL) has refuted an EU hemp group missive that the Ministry had changed its position regarding the novel fo"
  [3]=>
  string(211) "The German Food and Agriculture Ministry (BMEL) has refuted an EU hemp group missive that the Ministry had changed its position regarding the novel food requirement for some cannabidiol (CBD) extracts in the EU."
  ["description"]=>
  string(211) "The German Food and Agriculture Ministry (BMEL) has refuted an EU hemp group missive that the Ministry had changed its position regarding the novel food requirement for some cannabidiol (CBD) extracts in the EU."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "35"
  ["rss_id"]=>
  string(2) "35"
  [14]=>
  string(163) "https://www.nutraingredients.com/Article/2020/03/13/German-govt-and-Euro-hemp-trade-group-clash-over-CBD-status?utm_source=RSS_Feed&utm_medium=RSS&utm_campaign=RSS"
  ["blog_url"]=>
  string(163) "https://www.nutraingredients.com/Article/2020/03/13/German-govt-and-Euro-hemp-trade-group-clash-over-CBD-status?utm_source=RSS_Feed&utm_medium=RSS&utm_campaign=RSS"
  [15]=>
  string(19) "2020-03-13 14:00:00"
  ["add_date"]=>
  string(19) "2020-03-13 14:00:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-19 11:34:26"
  ["create_at"]=>
  string(19) "2020-03-19 11:34:26"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "8407"
  ["article_id"]=>
  string(4) "8407"
  [1]=>
  string(72) "DuPont bolsters APC Microbiome connection with new infant health project"
  ["article_title"]=>
  string(72) "DuPont bolsters APC Microbiome connection with new infant health project"
  [2]=>
  string(150) "DuPont Nutrition & Biosciences and APC Microbiome Ireland further strengthen their existing partnership with a new collaborative project looking into "
  ["short_description"]=>
  string(150) "DuPont Nutrition & Biosciences and APC Microbiome Ireland further strengthen their existing partnership with a new collaborative project looking into "
  [3]=>
  string(186) "DuPont Nutrition & Biosciences and APC Microbiome Ireland further strengthen their existing partnership with a new collaborative project looking into rebalancing babiesâ gut bacteria."
  ["description"]=>
  string(186) "DuPont Nutrition & Biosciences and APC Microbiome Ireland further strengthen their existing partnership with a new collaborative project looking into rebalancing babiesâ gut bacteria."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "35"
  ["rss_id"]=>
  string(2) "35"
  [14]=>
  string(155) "https://www.nutraingredients.com/Article/2020/03/13/DuPont-bolsters-APC-link-with-infant-health-project?utm_source=RSS_Feed&utm_medium=RSS&utm_campaign=RSS"
  ["blog_url"]=>
  string(155) "https://www.nutraingredients.com/Article/2020/03/13/DuPont-bolsters-APC-link-with-infant-health-project?utm_source=RSS_Feed&utm_medium=RSS&utm_campaign=RSS"
  [15]=>
  string(19) "2020-03-13 14:00:00"
  ["add_date"]=>
  string(19) "2020-03-13 14:00:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-19 11:34:26"
  ["create_at"]=>
  string(19) "2020-03-19 11:34:26"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "8459"
  ["article_id"]=>
  string(4) "8459"
  [1]=>
  string(92) "employee lied about coronavirus to get time off work, coworker sprayed Lysol at me, and more"
  ["article_title"]=>
  string(92) "employee lied about coronavirus to get time off work, coworker sprayed Lysol at me, and more"
  [2]=>
  string(159) "It’s five answers to five questions. Here we go… 1. My employee lied about being exposed to coronavirus One of my employees lied about being expos"
  ["short_description"]=>
  string(159) "It’s five answers to five questions. Here we go… 1. My employee lied about being exposed to coronavirus One of my employees lied about being expos"
  [3]=>
  string(1606) "
It’s five answers to five questions. Here we go… 1. My employee lied about being exposed to coronavirus One of my employees lied about being exposed to COVID-19. She called in to work saying she had gone back to her hometown over the weekend to visit family and was exposed while she was there. There […]
&#nl
&#nl
You may also like:
&#nl
&#nl
I think our employee lied about having cancer
&#nl
a teacher we employ forged vaccination paperwork for his child
&#nl
when your employer catches you forging a doctor's note to get out of work
&#nl
&#nl
&#nl
&#nl
employee lied about coronavirus to get time off work, coworker sprayed Lysol at me, and more was originally published by Alison Green on Ask a Manager.
&#nl"
  ["description"]=>
  string(1606) "
It’s five answers to five questions. Here we go… 1. My employee lied about being exposed to coronavirus One of my employees lied about being exposed to COVID-19. She called in to work saying she had gone back to her hometown over the weekend to visit family and was exposed while she was there. There […]
&#nl
&#nl
You may also like:
&#nl
&#nl
I think our employee lied about having cancer
&#nl
a teacher we employ forged vaccination paperwork for his child
&#nl
when your employer catches you forging a doctor's note to get out of work
&#nl
&#nl
&#nl
&#nl
employee lied about coronavirus to get time off work, coworker sprayed Lysol at me, and more was originally published by Alison Green on Ask a Manager.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "5"
  ["category"]=>
  string(1) "5"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "50"
  ["rss_id"]=>
  string(2) "50"
  [14]=>
  string(131) "https://www.askamanager.org/2020/03/employee-lied-about-coronavirus-to-get-time-off-work-coworker-sprayed-lysol-at-me-and-more.html"
  ["blog_url"]=>
  string(131) "https://www.askamanager.org/2020/03/employee-lied-about-coronavirus-to-get-time-off-work-coworker-sprayed-lysol-at-me-and-more.html"
  [15]=>
  string(19) "2020-03-13 12:03:17"
  ["add_date"]=>
  string(19) "2020-03-13 12:03:17"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-19 11:34:42"
  ["create_at"]=>
  string(19) "2020-03-19 11:34:42"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "8354"
  ["article_id"]=>
  string(4) "8354"
  [1]=>
  string(78) "SERINUS CARE-AT-HOME LEADING SOLUTION TO FIGHT CORONA VIRUS COVID 19 PANDEMIC "
  ["article_title"]=>
  string(78) "SERINUS CARE-AT-HOME LEADING SOLUTION TO FIGHT CORONA VIRUS COVID 19 PANDEMIC "
  [2]=>
  string(129) "SERINUS HEALTH RECIPIENT OF INTELLIGENT HEALTH ASSOCIATION AWARD SERINUS HEALTH RECIPIENT OF INTELLIGENT HEALTH ASSOCIATION AWARD"
  ["short_description"]=>
  string(129) "SERINUS HEALTH RECIPIENT OF INTELLIGENT HEALTH ASSOCIATION AWARD SERINUS HEALTH RECIPIENT OF INTELLIGENT HEALTH ASSOCIATION AWARD"
  [3]=>
  string(140) "SERINUS HEALTH RECIPIENT OF INTELLIGENT HEALTH ASSOCIATION AWARD 
SERINUS HEALTH RECIPIENT OF INTELLIGENT HEALTH ASSOCIATION AWARD
"
  ["description"]=>
  string(140) "SERINUS HEALTH RECIPIENT OF INTELLIGENT HEALTH ASSOCIATION AWARD 
SERINUS HEALTH RECIPIENT OF INTELLIGENT HEALTH ASSOCIATION AWARD
"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "26"
  ["rss_id"]=>
  string(2) "26"
  [14]=>
  string(148) "http://www.globenewswire.com/news-release/2020/03/13/2000016/0/en/SERINUS-CARE-AT-HOME-LEADING-SOLUTION-TO-FIGHT-CORONA-VIRUS-COVID-19-PANDEMIC.html"
  ["blog_url"]=>
  string(148) "http://www.globenewswire.com/news-release/2020/03/13/2000016/0/en/SERINUS-CARE-AT-HOME-LEADING-SOLUTION-TO-FIGHT-CORONA-VIRUS-COVID-19-PANDEMIC.html"
  [15]=>
  string(19) "2020-03-13 10:30:00"
  ["add_date"]=>
  string(19) "2020-03-13 10:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-19 11:34:08"
  ["create_at"]=>
  string(19) "2020-03-19 11:34:08"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "8419"
  ["article_id"]=>
  string(4) "8419"
  [1]=>
  string(68) "Rubius Drops Rare Diseases, Turns to Cancer and Autoimmune Disorders"
  ["article_title"]=>
  string(68) "Rubius Drops Rare Diseases, Turns to Cancer and Autoimmune Disorders"
  [2]=>
  string(150) "Rubius Therapeutics is dropping its lead drug candidate—and its focus on rare diseases—in favor of earlier-stage cell therapies that it ha"
  ["short_description"]=>
  string(150) "Rubius Therapeutics is dropping its lead drug candidate—and its focus on rare diseases—in favor of earlier-stage cell therapies that it ha"
  [3]=>
  string(397) "Rubius Therapeutics is dropping its lead drug candidate—and its focus on rare diseases—in favor of earlier-stage cell therapies that it has been developing for oncology and autoimmune disorders. The Cambridge, MA-based company disclosed the strategy shift Thursday in its report of fourth quarter and full year 2019 financial results. After the announcement, shares of Rubius […]"
  ["description"]=>
  string(397) "Rubius Therapeutics is dropping its lead drug candidate—and its focus on rare diseases—in favor of earlier-stage cell therapies that it has been developing for oncology and autoimmune disorders. The Cambridge, MA-based company disclosed the strategy shift Thursday in its report of fourth quarter and full year 2019 financial results. After the announcement, shares of Rubius […]"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "36"
  ["rss_id"]=>
  string(2) "36"
  [14]=>
  string(106) "https://xconomy.com/boston/2020/03/12/rubius-drops-rare-diseases-turns-to-cancer-and-autoimmune-disorders/"
  ["blog_url"]=>
  string(106) "https://xconomy.com/boston/2020/03/12/rubius-drops-rare-diseases-turns-to-cancer-and-autoimmune-disorders/"
  [15]=>
  string(19) "2020-03-13 09:49:01"
  ["add_date"]=>
  string(19) "2020-03-13 09:49:01"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-19 11:34:27"
  ["create_at"]=>
  string(19) "2020-03-19 11:34:27"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "8569"
  ["article_id"]=>
  string(4) "8569"
  [1]=>
  string(130) "Johnson & Johnson Announces Collaboration with the Beth Israel Deaconess Medical Center to Accelerate COVID-19 Vaccine Development"
  ["article_title"]=>
  string(130) "Johnson & Johnson Announces Collaboration with the Beth Israel Deaconess Medical Center to Accelerate COVID-19 Vaccine Development"
  [2]=>
  string(150) "NEW BRUNSWICK, N.J., March 13, 2020 – Johnson & Johnson today announced that its Janssen Pharmaceutical Companies have entered a c"
  ["short_description"]=>
  string(150) "NEW BRUNSWICK, N.J., March 13, 2020 – Johnson & Johnson today announced that its Janssen Pharmaceutical Companies have entered a c"
  [3]=>
  string(251) "NEW BRUNSWICK, N.J., March 13, 2020 – Johnson & Johnson today announced that its Janssen Pharmaceutical Companies have entered a collaboration with the Beth Israel Deaconess Medical Center (BIDMC) to support the development of a..."
  ["description"]=>
  string(251) "NEW BRUNSWICK, N.J., March 13, 2020 – Johnson & Johnson today announced that its Janssen Pharmaceutical Companies have entered a collaboration with the Beth Israel Deaconess Medical Center (BIDMC) to support the development of a..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "15"
  ["rss_id"]=>
  string(2) "15"
  [14]=>
  string(300) "https://www.drugs.com/clinical_trials/johnson-johnson-announces-collaboration-beth-israel-deaconess-medical-center-accelerate-covid-19-18472.html?utm_source=ddc&utm_medium=rss&utm_campaign=Johnson+%26+Johnson+Announces+Collaboration+with+the+Beth+Israel+Deaconess+Medical+Center+to+Accelerate+COVID-1"
  ["blog_url"]=>
  string(300) "https://www.drugs.com/clinical_trials/johnson-johnson-announces-collaboration-beth-israel-deaconess-medical-center-accelerate-covid-19-18472.html?utm_source=ddc&utm_medium=rss&utm_campaign=Johnson+%26+Johnson+Announces+Collaboration+with+the+Beth+Israel+Deaconess+Medical+Center+to+Accelerate+COVID-1"
  [15]=>
  string(19) "2020-03-13 09:03:35"
  ["add_date"]=>
  string(19) "2020-03-13 09:03:35"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-31 11:18:05"
  ["create_at"]=>
  string(19) "2020-03-31 11:18:05"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "8570"
  ["article_id"]=>
  string(4) "8570"
  [1]=>
  string(109) "Update on Phase III GY004 Trial for Cediranib Added to Lynparza in Platinum-Sensitive Relapsed Ovarian Cancer"
  ["article_title"]=>
  string(109) "Update on Phase III GY004 Trial for Cediranib Added to Lynparza in Platinum-Sensitive Relapsed Ovarian Cancer"
  [2]=>
  string(150) "12 March 2020 -- AstraZeneca and MSD Inc., Kenilworth, N.J., US (MSD: known as Merck & Co., Inc. inside the US and Canada) today announced high-le"
  ["short_description"]=>
  string(150) "12 March 2020 -- AstraZeneca and MSD Inc., Kenilworth, N.J., US (MSD: known as Merck & Co., Inc. inside the US and Canada) today announced high-le"
  [3]=>
  string(249) "12 March 2020 -- AstraZeneca and MSD Inc., Kenilworth, N.J., US (MSD: known as Merck & Co., Inc. inside the US and Canada) today announced high-level results from the Phase III GY004 trial, led by NRG Oncology and sponsored by the US National..."
  ["description"]=>
  string(249) "12 March 2020 -- AstraZeneca and MSD Inc., Kenilworth, N.J., US (MSD: known as Merck & Co., Inc. inside the US and Canada) today announced high-level results from the Phase III GY004 trial, led by NRG Oncology and sponsored by the US National..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "15"
  ["rss_id"]=>
  string(2) "15"
  [14]=>
  string(298) "https://www.drugs.com/clinical_trials/update-phase-iii-gy004-trial-cediranib-added-lynparza-platinum-sensitive-relapsed-ovarian-cancer-18488.html?utm_source=ddc&utm_medium=rss&utm_campaign=Update+on+Phase+III+GY004+Trial+for+Cediranib+Added+to+Lynparza+in+Platinum-Sensitive+Relapsed+Ovarian+Cancer"
  ["blog_url"]=>
  string(298) "https://www.drugs.com/clinical_trials/update-phase-iii-gy004-trial-cediranib-added-lynparza-platinum-sensitive-relapsed-ovarian-cancer-18488.html?utm_source=ddc&utm_medium=rss&utm_campaign=Update+on+Phase+III+GY004+Trial+for+Cediranib+Added+to+Lynparza+in+Platinum-Sensitive+Relapsed+Ovarian+Cancer"
  [15]=>
  string(19) "2020-03-13 06:03:31"
  ["add_date"]=>
  string(19) "2020-03-13 06:03:31"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-31 11:18:05"
  ["create_at"]=>
  string(19) "2020-03-31 11:18:05"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "8420"
  ["article_id"]=>
  string(4) "8420"
  [1]=>
  string(72) "G1’s Demaree Jumps to Karyopharm for Chief Commercial Officer Job"
  ["article_title"]=>
  string(72) "G1’s Demaree Jumps to Karyopharm for Chief Commercial Officer Job"
  [2]=>
  string(150) "John Demaree is joining Karyopharm Therapeutics (NASDAQ: KPTI) as its chief commercial officer, the same position he held most recently at G1 Therapeu"
  ["short_description"]=>
  string(150) "John Demaree is joining Karyopharm Therapeutics (NASDAQ: KPTI) as its chief commercial officer, the same position he held most recently at G1 Therapeu"
  [3]=>
  string(397) "John Demaree is joining Karyopharm Therapeutics (NASDAQ: KPTI) as its chief commercial officer, the same position he held most recently at G1 Therapeutics (NASDAQ: GTHX). His experience also includes positions at Astellas Pharma, Abbott Laboratories (NYSE: ABT), Novartis (NYSE: NVS), and Eli Lilly (NYSE: LLY). Newton, MA-based Karyopharm recently reported positive results from a Phase […]"
  ["description"]=>
  string(397) "John Demaree is joining Karyopharm Therapeutics (NASDAQ: KPTI) as its chief commercial officer, the same position he held most recently at G1 Therapeutics (NASDAQ: GTHX). His experience also includes positions at Astellas Pharma, Abbott Laboratories (NYSE: ABT), Novartis (NYSE: NVS), and Eli Lilly (NYSE: LLY). Newton, MA-based Karyopharm recently reported positive results from a Phase […]"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "36"
  ["rss_id"]=>
  string(2) "36"
  [14]=>
  string(103) "https://xconomy.com/boston/2020/03/12/g1s-demaree-jumps-to-karyopharm-for-chief-commercial-officer-job/"
  ["blog_url"]=>
  string(103) "https://xconomy.com/boston/2020/03/12/g1s-demaree-jumps-to-karyopharm-for-chief-commercial-officer-job/"
  [15]=>
  string(19) "2020-03-13 04:47:12"
  ["add_date"]=>
  string(19) "2020-03-13 04:47:12"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-19 11:34:27"
  ["create_at"]=>
  string(19) "2020-03-19 11:34:27"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "8421"
  ["article_id"]=>
  string(4) "8421"
  [1]=>
  string(71) "Pfizer’s Gupta Joins G1 Therapeutics as Chief Commercial Officer"
  ["article_title"]=>
  string(71) "Pfizer’s Gupta Joins G1 Therapeutics as Chief Commercial Officer"
  [2]=>
  string(150) "G1 Therapeutics (NASDAQ: GTHX) has appointed Soma Gupta to serve as its chief commercial officer. She was most recently vice president of global marke"
  ["short_description"]=>
  string(150) "G1 Therapeutics (NASDAQ: GTHX) has appointed Soma Gupta to serve as its chief commercial officer. She was most recently vice president of global marke"
  [3]=>
  string(351) "G1 Therapeutics (NASDAQ: GTHX) has appointed Soma Gupta to serve as its chief commercial officer. She was most recently vice president of global marketing for rare disease at Pfizer (NYSE: PFE). Durham, NC-based G1 has submitted a rolling application for FDA approval of its lead drug, trilacilib, as a treatment for patients with small cell […]"
  ["description"]=>
  string(351) "G1 Therapeutics (NASDAQ: GTHX) has appointed Soma Gupta to serve as its chief commercial officer. She was most recently vice president of global marketing for rare disease at Pfizer (NYSE: PFE). Durham, NC-based G1 has submitted a rolling application for FDA approval of its lead drug, trilacilib, as a treatment for patients with small cell […]"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "36"
  ["rss_id"]=>
  string(2) "36"
  [14]=>
  string(110) "https://xconomy.com/raleigh-durham/2020/03/12/pfizers-gupta-joins-g1-therapeutics-as-chief-commercial-officer/"
  ["blog_url"]=>
  string(110) "https://xconomy.com/raleigh-durham/2020/03/12/pfizers-gupta-joins-g1-therapeutics-as-chief-commercial-officer/"
  [15]=>
  string(19) "2020-03-13 04:42:04"
  ["add_date"]=>
  string(19) "2020-03-13 04:42:04"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-19 11:34:27"
  ["create_at"]=>
  string(19) "2020-03-19 11:34:27"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "8380"
  ["article_id"]=>
  string(4) "8380"
  [1]=>
  string(60) "Facebook language changes before an emergency hospital visit"
  ["article_title"]=>
  string(60) "Facebook language changes before an emergency hospital visit"
  [2]=>
  string(150) "A new study reveals that the language people use on Facebook subtly changes before they make a visit to the emergency department (ED). A team of resea"
  ["short_description"]=>
  string(150) "A new study reveals that the language people use on Facebook subtly changes before they make a visit to the emergency department (ED). A team of resea"
  [3]=>
  string(371) "A new study reveals that the language people use on Facebook subtly changes before they make a visit to the emergency department (ED). A team of researchers provides more evidence that social media is often an unseen signal of medical distress and could be used to better understand the contexts in which patients seek care, such as during the current COVID-19 pandemic. "
  ["description"]=>
  string(371) "A new study reveals that the language people use on Facebook subtly changes before they make a visit to the emergency department (ED). A team of researchers provides more evidence that social media is often an unseen signal of medical distress and could be used to better understand the contexts in which patients seek care, such as during the current COVID-19 pandemic. "
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "29"
  ["rss_id"]=>
  string(2) "29"
  [14]=>
  string(62) "https://www.sciencedaily.com/releases/2020/03/200312163828.htm"
  ["blog_url"]=>
  string(62) "https://www.sciencedaily.com/releases/2020/03/200312163828.htm"
  [15]=>
  string(19) "2020-03-13 04:38:28"
  ["add_date"]=>
  string(19) "2020-03-13 04:38:28"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-19 11:34:17"
  ["create_at"]=>
  string(19) "2020-03-19 11:34:17"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "8422"
  ["article_id"]=>
  string(4) "8422"
  [1]=>
  string(64) "Harbour BioMed Tacks on $75M to Advance Broad Biologics Pipeline"
  ["article_title"]=>
  string(64) "Harbour BioMed Tacks on $75M to Advance Broad Biologics Pipeline"
  [2]=>
  string(150) "A biotech born out of an antibody platform company has added another $75 million to its investment haul, money it says will allow it to advance its cl"
  ["short_description"]=>
  string(150) "A biotech born out of an antibody platform company has added another $75 million to its investment haul, money it says will allow it to advance its cl"
  [3]=>
  string(376) "A biotech born out of an antibody platform company has added another $75 million to its investment haul, money it says will allow it to advance its clinical-stage compounds and continue to build its portfolio of earlier-stage therapeutics. Shanghai-based Harbour BioMed emerged in 2016 after acquiring technology developed by Harbour Antibodies, a Dutch company that […]"
  ["description"]=>
  string(376) "A biotech born out of an antibody platform company has added another $75 million to its investment haul, money it says will allow it to advance its clinical-stage compounds and continue to build its portfolio of earlier-stage therapeutics. Shanghai-based Harbour BioMed emerged in 2016 after acquiring technology developed by Harbour Antibodies, a Dutch company that […]"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "36"
  ["rss_id"]=>
  string(2) "36"
  [14]=>
  string(102) "https://xconomy.com/boston/2020/03/12/harbour-biomed-tacks-on-75m-to-advance-broad-biologics-pipeline/"
  ["blog_url"]=>
  string(102) "https://xconomy.com/boston/2020/03/12/harbour-biomed-tacks-on-75m-to-advance-broad-biologics-pipeline/"
  [15]=>
  string(19) "2020-03-13 02:31:25"
  ["add_date"]=>
  string(19) "2020-03-13 02:31:25"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-19 11:34:27"
  ["create_at"]=>
  string(19) "2020-03-19 11:34:27"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "8381"
  ["article_id"]=>
  string(4) "8381"
  [1]=>
  string(82) "Study details first known person-to-person transmission of new coronavirus in U.S."
  ["article_title"]=>
  string(82) "Study details first known person-to-person transmission of new coronavirus in U.S."
  [2]=>
  string(150) "New research describes in detail the first locally-transmitted case of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes COVI"
  ["short_description"]=>
  string(150) "New research describes in detail the first locally-transmitted case of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes COVI"
  [3]=>
  string(262) "New research describes in detail the first locally-transmitted case of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes COVID-19, in the USA, from a woman who had recently traveled to China and transmitted the infection to her husband. "
  ["description"]=>
  string(262) "New research describes in detail the first locally-transmitted case of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes COVID-19, in the USA, from a woman who had recently traveled to China and transmitted the infection to her husband. "
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "29"
  ["rss_id"]=>
  string(2) "29"
  [14]=>
  string(62) "https://www.sciencedaily.com/releases/2020/03/200312123641.htm"
  ["blog_url"]=>
  string(62) "https://www.sciencedaily.com/releases/2020/03/200312123641.htm"
  [15]=>
  string(19) "2020-03-13 00:36:41"
  ["add_date"]=>
  string(19) "2020-03-13 00:36:41"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-19 11:34:18"
  ["create_at"]=>
  string(19) "2020-03-19 11:34:18"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}